Mast cells in human airways: The culprit?

European Respiratory Review

Volumn 23, Issue 133, 2014, Pages 299-307

  Erjefält, Jonas S ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; HUMAN; HYPERSENSITIVITY; LUNG ALVEOLUS; MAST CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; RESPIRATORY SYSTEM;

HUMANS; HYPERSENSITIVITY; MAST CELLS; PULMONARY ALVEOLI; RESPIRATORY SYSTEM;

EID: 84906849980     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005014     Document Type: Review

References (62)

1. Taylor ML, Metcalfe DD. Mast cells in allergy and host defense. Allergy Asthma Proc 2001; 22: 115-119.
2. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol 2014; 14: 478-494.
3. Metz M, Grimbaldeston MA, Nakae S, et al. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 2007; 217: 304-328.
4. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77: 1033-1079.
5. Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 2006; 117: 1277-1284.
6. Andersson CK, Mori M, Bjermer L, et al. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 206-217.
7. Ballarin A, Bazzan E, Zenteno RH, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 233-239.
8. Overed-Sayer C, Rapley L, Mustelin T, et al. Are mast cells instrumental for fibrotic diseases? Front Pharmacol 2013; 4: 174.
9. Andersson CK, Andersson-Sjoland A, Mori M, et al. Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respir Res 2011; 12: 139.
10. Cha SI, Chang CS, Kim EK, et al. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Histopathology 2012; 61: 98-106.
11. Wygrecka M, Dahal BK, Kosanovic D, et al. Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-alpha/Raf-1/p44/42 signaling pathway. Am J Pathol 2013; 182: 2094-2108.
12. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010; 10: 440-452.
13. Graham AC, Hilmer KM, Zickovich JM, et al. Inflammatory response of mast cells during influenza A virus infection is mediated by active infection and RIG-I signaling. J Immunol 2013; 190: 4676-4684.
14. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18: 693-704.
15. Persson CG, Erjefalt JS, Greiff L, et al. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur Respir J 1998; 11: 958-970.
16. McDonald DM, Thurston G, Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999; 6: 7-22.
17. Lundequist A, Pejler G. Biological implications of preformed mast cell mediators. Cell Mol Life Sci 2011; 68: 965-975.
18. Metz M, Maurer M. Mast cells - key effector cells in immune responses. Trends Immunol 2007; 28: 234-241.
19. Holgate ST, Salvi SS. Mast cell tryptase as a proinflammatory mediator in late-phase asthmatic response. Curr Allergy Asthma Rep 2002; 2: 105-106.
20. Galli SJ, Kalesnikoff J, Grimbaldeston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786.
21. St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol 2013; 190: 4458-4463.
22. Hofmann AM, Abraham SN. New roles for mast cells in pathogen defense and allergic disease. Discov Med 2010; 9: 79-83.
23. Galli SJ, Maurer M, Lantz CS. Mast cells as sentinels of innate immunity. Curr Opin Immunol 1999; 11: 53-59.
24. Shikhagaie MM, Andersson CK, Mori M, et al. Mapping of TLR5 and TLR7 in central and distal human airways and identification of reduced TLR expression in severe asthma. Clin Exp Allergy 2014; 44: 184-196.
25. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010; 35: 1209-1215.
26. Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128: 1165-1174.
27. Edwards MR, Bartlett NW, Hussell T, et al. The microbiology of asthma. Nat Rev Microbiol 2012; 10: 459-471.
28. Ishizuka T, Okayama Y, Kobayashi H, et al. Interleukin-10 is localized to and released by human lung mast cells. Clin Exp Allergy 1999; 29: 1424-1432.
29. Piliponsky AM, Chen CC, Rios EJ, et al. The chymase mouse mast cell protease 4 degrades TNF, limits inflammation, and promotes survival in a model of sepsis. Am J Pathol 2012; 181: 875-886.
30. Waern I, Karlsson I, Thorpe M, et al. Mast cells limit extracellular levels of IL-13 via a serglycin proteoglycan-serine protease axis. Biol Chem 2012; 393: 1555-1567.
31. Xue L, Salimi M, Panse I, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 2014; 133: 1184-1194.
32. Enerback L. Mast cells in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand 1966; 66: 289-302.
33. Irani AM, Schwartz LB. Mast cell heterogeneity. Clin Exp Allergy 1989; 19: 143-155.
34. Lee TD, Swieter M, Bienenstock J, et al. Heterogeneity in mast cell populations. Clin Immunol Rev 1985; 4: 143-199.
35. Moon TC, St Laurent CD, Morris KE, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3: 111-128.
36. Brightling CE, Bradding P, Symon FA, et al. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346: 1699-1705.
37. Balzar S, Chu HW, Strand M, et al. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005; 171: 431-439.
38. Andersson CK, Bergqvist A, Mori M, et al. Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. J Allergy Clin Immunol 2011; 127: 905-912.
39. Andersson CK, Tufvesson E, Aronsson D, et al. Alveolar mast cells shift to an FceRI-expressing phenotype in mild atopic asthma: a novel feature in allergic asthma pathology. Allergy 2011; 66: 1590-1597.
40. Kawanami O, Ferrans VJ, Fulmer JD, et al. Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest 1979; 40: 717-734.
41. Andersson CK, Mori M, Bjermer L, et al. Novel site-specific mast cell subpopulations in the human lung. Thorax 2009; 64: 297-305.
42. Bradding P. Human lung mast cell heterogeneity. Thorax 2009; 64: 278-280.
43. Fox B, Bull TB, Guz A. Mast cells in the human alveolar wall: an electronmicroscopic study. J Clin Pathology 1981; 34: 1333-1342.
44. Warton A, Papadimitriou JM, Goldie RG, et al. An ultrastructural study of mast cells in the alveolar wall of normal and asthmatic lung. Aust J Exp Biol Med Sci 1986; 64: 435-444.
45. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
46. Holgate ST. Stratified approaches to the treatment of asthma. Br J Clin Pharmacol 2013; 76: 277-291.
47. Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalizedmedicine. J Asthma 2014; 13: 1-8.
48. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
49. Bergqvist A, Andersson CK, Hoffmann HJ, et al. Marked epithelial cell pathology and leukocyte paucity in persistently symptomatic severe asthma. Am J Respir Crit Care Med 2013; 188: 1475-1477.
50. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510.
51. Sutherland ER, Martin RJ. Distal lung inflammation in asthma. Ann Allergy Asthma Immunol 2002; 89: 119-124.
52. de Magalhaes Simoes S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005; 35: 602-611.
53. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003; 112: 58-63.
54. Nihlberg K, Andersson-Sjoland A, Tufvesson E, et al. Altered matrix production in the distal airways of individuals with asthma. Thorax 2010; 65: 670-676.
55. Bergqvist A, Andersson CK, Mori M, et al. Alveolar T-helper type 2 immunity in atopic asthma is associated with poor clinical control. Clin Sci 2014 [In press DOI: 10.1042/CS20140309].
56. Kiyokawa H, Matsumoto H, Nakaji H, et al. Centrilobular opacities in the asthmatic lung successfully treated with inhaled ciclesonide and tiotropium: with assessment of alveolar nitric oxide levels. Allergol Int 2011; 60: 381-385.
57. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
58. Kosanovic D, Dahal BK, Wygrecka M, et al. Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis? Histol Histopathol 2013; 28: 691-699.
59. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol 2008; 9: 1215-1223.
60. Metcalfe DD, Peavy RD, Gilfillan AM. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 2009; 124: 639-646.
61. Harvima IT, Levi-Schaffer F, Draber P, et al. Molecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 2014 [In press DOI 10.1016/j.jaci.2014.03.007].
62. Reber LL, Frossard N. Targeting mast cells in inflammatory diseases. Pharmacol Ther 2014; 142: 416-435.